CTLA4 and neoplasm: Correspondingly developed immune checkpoint inhibitors (ICIs), such as anti-PD1/PD-L1 and anti-CTLA-4 can block the interaction between tumor cells that express immune checkpoint molecules and immune cells, thereby blocking the inhibition of tumor cells to immune cells.